OCTOBER 22, 2020
Grants Awarded

Extramurally funded research grants awarded to Rogel Cancer Center members

Program Key:
CB - Cancer Biology; CG - Cancer Genetics; CHI - Cancer Hematopoiesis and Immunology; DT - Developmental Therapeutics; HBO - Health Behavior and Outcomes; CEP - Cancer Epidemiology and Prevention; TACR - Translational and Clinical Research
In the spotlight
Multi-investigator NHLBI P01 led by Cancer Hematopoiesis and Immunology Program Leader
Pavan Reddy, M.D., along with project and core leaders Costas Lyssiotis, Ph.D., Gabriel Nunez, M.D., Thomas Schmidt, Ph.D., Muneesh Tewari, M.D., Ph.D., Greg Dick, Ph.D., and Eric Martens, Ph.D., were awarded $11.2M by the National Heart, Lung, and Blood Institute (NHLBI) for a P01 titled “Host and Microbial Metabolism in Graft versus Host Disease.” This Program Project award highlights the intra- and inter-programmatic collaborations of three Rogel Cancer Center Research Programs: Cancer Hematopoiesis and Immunology, Cancer Biology, and Translational and Clinical Research.
Pavan Reddy, M.D.
Multi-PI, Multi-Institutional Collaboration from Cancer Epidemiology and Prevention
Rafael Meza, Ph.D. (contact PI), and colleagues from Harvard, Georgetown, Glasgow, Stanford, and Yale were awarded a $8.7M U01 from the National Cancer Institute (NCI) for “Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions.” The study seeks to quantify the effects of future tobacco control interventions, improvements in lung cancer screening and other emerging early detection strategies, innovations in lung cancer treatment, and their synergistic interactions, on lung cancer rates and overall mortality in the U.S. and globally.
Rafael Meza, Ph.D.
Other $100K+ Extramural Grants Awarded in September

Marilia Cascalho, M.D., Ph.D., and Dongshan Yang, Ph.D.: NIGMS R21 ($429K) “A Novel Rabbit Model for Easy Monoclonal Antibody Production” (CHI)

David Ferguson, M.D., Ph.D.: NHLBI R56 ($609K) “The MRN complex in Lymphocyte Development and Genome Stability” (CG)

Amanda Garner, Ph.D.: NIGMS R01 ($1.3M) “Delineating the Biology of Translational Repressor 4E-BP1” (DT)

Reshma Jagsi, M.D.: NIGMS R01 ($1.7M) “Peer Mentoring to Overcome Obstacles for Midcareer Women Clinician-Scientists in Academic Medicine” (HBO)

Hyun Min Kang, Ph.D., and Sebastian Zoellner, Ph.D.: NHGRI R01 ($1.4M) “Leveraging Long-range Haplotypes in Sequencing Data to Advance Large Scale Genetic Studies” (CG)

Jie Liu, Ph.D., NHGRI R35 ($2.2M) “Joint Analysis of 3D Chromatin Organization and 1D Epigenome” (CB)

Jie Liu, Ph.D., NIHOD R03 ($266K) “A Database for High-resolution Chromatin Contact Maps and Human Genetic Variants” (CB)

David Lombard, M.D., Ph.D.: NIEHS R01 ($429K) “Elucidating Epigenetic Mechanisms of Cellular Cadmium Toxicity” (CG)

Andrew Tai, M.D., Ph.D., Alice Telesnitsky, Ph.D., and Jeffrey Kidd, Ph.D.: NIGMS R21 ($429K) “HIV-1 Genomic RNA Integrity” (CB, CG)

Other External

Kelley Kidwell, Ph.D.: $800K from the Department of Food and Drug Administration for “Innovative Randomized Trial Designs and Bayesian Analyses for Registration of a Drug for Rare Diseases in Small Samples” (TACR)

Matthias Kretzler, M.D.: $2.3M from Retrophin, LLC. For “NEPTUNE Public-Private Partnership” (TACR)

Goutham Narla, M.D., Ph.D.: $1.5M from Rappta Therapeutics Oy for “Testing of Small Molecule PP2A Activators in Cellular and In Vivo Systems” (CG)
Rogel Cancer Center List of Internal and External Funding Opportunities
We update and maintain a comprehensive list of funding opportunities for cancer research.

Please forward this message to your fellow cancer center colleagues.